Alembic Pharmaceuticals Ltd. Consolidated Results for quarter ended 30.09.2011
Revenues up 24% at Rs 398 crores against Rs. 321 crores in PY PBT up 47% at Rs 45 crores against Rs. 30.6 crores in PY
Editors Synopsis
• Net sales up 24% at Rs 398 crores against Rs. 321 crores in corresponding quarter last year
• Domestic formulations up 10% at Rs. 227 crores against Rs. 207 crores in corresponding quarter last year
• International Generics up by 79% to Rs. 71 crores vis-àvis Rs. 40 crores last year
• Total API sales up 47% at Rs. 82 crores against Rs. 56 crores in corresponding quarter last year
• Profit before tax up by 47% at Rs. 45.04 crores against Rs. 30.60 crores in corresponding quarter in last year
Vadodara, 19th October, 2011.
Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 24% increase in revenues to Rs 398.05 crores for the quarter ended 30th September 2011, compared to Rs 321.17 crores in the corresponding quarter last year. The Company posted an impressive 47% growth in profit before tax at Rs. 45.04 crores for the quarter ended September 2011 against Rs 30.60 crores posted in corresponding quarter last fiscal.
EBIDTA margins for quarter ended September 11 up at 15.19% from 13.21% for corresponding quarter last year.
International Business
International Generics to the regulated markets grew by 79% to Rs. 71.38 crores from Rs. 39.79 Crores over the corresponding quarter last year.
Formulations sales to ROW markets amounted to Rs. 12.04 crores against Rs. 14.95 crores in corresponding quarter last year.
Export of API products grew by 50% to Rs. 60.44 crores from Rs. 40.41 crores over corresponding quarter last year.
Cumulative DMF filings at 56. Cumulative ANDA filings at 41. Cumulative ANDA approvals now stands at 15.
Domestic Formulation Business
The domestic formulation business posted sales of Rs. 226.92 crores against Rs. 206.83 crores registering 10% growth over the corresponding quarter last year.
Alembic has maintained a market share of 1.86%. The positive impact of the restructuring undertaken in the recent past is evident from the encouraging numbers.
Alembic has four brands in the list of top 300 brands of the industry i.e. ‘Azithral’ , ‘Roxid’, ‘Althrocin’, and ‘Wikoryl’.
Domestic API Business
Domestic API sales recorded a growth of 40% at Rs. 22.01 crores against Rs. 15.69 crores of PY.
Summary of total revenue (consolidated) for the quarter: (Rs. in Lacs)
Particulars Q2 FY12 Q2 FY11 % Change
Formulation
Domestic 22692 20683 10%
International Branded 1204 1495 (-)19%
International Generics 7138 3979 79%
API
Domestic 2201 1569 40%
International 6044 4041 50%
Export incentives 526 350 50%
Total 39805 32117 24%
The Profit break-up for the quarter: (Rs. in Lacs)
Consolidated
Particulars Q2 FY12 Q2 FY11 % Change
Operating Income
6047 4243 43%
Profit Before Tax 4504 3060 47%
Net Profit after Tax 3804 2521 51%
The previous year’s figures are approx. and unaudited numbers of relevant businesses which were then part of Alembic Limited. These are given just for comparison purpose.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of antiinfective
drugs in India.
Alembic’s manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
